153 related articles for article (PubMed ID: 3566043)
21. Polychemotherapy in ovarian cancer: treatment with Adriamycin, BCNU and cyclophosphamide vs. Adriamycin and cyclophosphamide.
Mazzei T; Bonazza M; Amunni G; Scarselli G; Branconi F; Massi GB
Chemioterapia; 1984 Feb; 3(1):10-5. PubMed ID: 6535650
[TBL] [Abstract][Full Text] [Related]
22. [A case of neo-JP therapy in the treatment of ovarian carcinoma].
Matsunami K; Takagi H; Hasegawa Y
Gan To Kagaku Ryoho; 1995 Jan; 22(1):153-5. PubMed ID: 7826073
[No Abstract] [Full Text] [Related]
23. [Evaluation of the renal function in patients with ovarian carcinoma subjected to polychemotherapy including cisplatin or carboplatin].
Gadducci A; Facchini V; Dell'Arciprete T; Del Bravo B; Galigani P; Palla R; Fioretti P
Minerva Ginecol; 1988 Jan; 40(1):33-8. PubMed ID: 3287233
[No Abstract] [Full Text] [Related]
24. [Treatment of advanced ovarian cancer].
de Gramont A; Krulik M; Pigne A; Brissaud P; Sirinelli A; Hubert D; Zylberait D; Debray J
Sem Hop; 1984 Mar; 60(14):957-60. PubMed ID: 6326283
[TBL] [Abstract][Full Text] [Related]
25. Short-term effects of chemotherapy-surgery-chemotherapy regimen on clinically inoperable advanced ovarian cancer.
Feng Y; Sun T
Chin Med J (Engl); 1998 Aug; 111(8):722-5. PubMed ID: 11245027
[TBL] [Abstract][Full Text] [Related]
26. [Treatment of patients with ovarian carcinoma: experimental and clinical studies].
Kikuchi Y; Kita T; Iwano I; Miyauchi M; Oomori K; Kizawa I; Kato K
Nihon Sanka Fujinka Gakkai Zasshi; 1988 Jul; 40(7):933-5. PubMed ID: 3418201
[No Abstract] [Full Text] [Related]
27. Cisplatin sensitivity of ovarian cancer in the histoculture drug response assay correlates to clinical response to combination chemotherapy with cisplatin, doxorubicin and cyclophosphamide.
Ohie S; Udagawa Y; Kozu A; Komuro Y; Aoki D; Nozawa S; Moossa AR; Hoffman RM
Anticancer Res; 2000; 20(3B):2049-54. PubMed ID: 10928150
[TBL] [Abstract][Full Text] [Related]
28. [An evaluation of two postoperative chemotherapy protocols in ovarian common epithelial cancer: a comparison of continuous and intermittent hospitalization].
Sakamoto H; Suzuki H; Hayakawa S; Kiseki Y; Miyakawa Y; Ohkubo Y; Watanabe Y; Takami M; Kashiwazaki K; Tanaka H
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Sep; 41(9):1491-4. PubMed ID: 2584826
[No Abstract] [Full Text] [Related]
29. [Chemotherapy of ovarian tumors using cis-platin].
Laurová L; Kobilková J; Novotná J; Motlík K; Fricová M; Hornický J
Cesk Gynekol; 1987 Feb; 52(1):41-4. PubMed ID: 3568161
[No Abstract] [Full Text] [Related]
30. Cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced endometrial carcinoma.
Turbow MM; Ballon SC; Sikic BI; Koretz MM
Cancer Treat Rep; 1985 May; 69(5):465-7. PubMed ID: 4039978
[TBL] [Abstract][Full Text] [Related]
31. [A carcinosarcoma of the ovary: a case report and a review].
Ishihara H; Kanamori Y; Morishita K; Minagawa Y; Kigawa J; Matsui K
Gan No Rinsho; 1990 Sep; 36(11):2105-9. PubMed ID: 2232179
[TBL] [Abstract][Full Text] [Related]
32. [Comparative research on different treatment regimens in disseminated cancer of the ovaries].
Marinov L; Koĭnov K; Tsekova V; Velikova M
Akush Ginekol (Sofiia); 1987; 26(1):49-52. PubMed ID: 3592111
[No Abstract] [Full Text] [Related]
33. Randomized comparison of hexamethylmelamine, adriamycin, cyclophosphamide (HAC) vs. cisplatin, adriamycin, cyclophosphamide (PAC) in advanced ovarian cancer: long-term results.
Sessa C; Colombo N; Bolis G; Marsoni S; Mangioni C
Cancer Treat Rev; 1991 Mar; 18 Suppl A():37-46. PubMed ID: 1904308
[No Abstract] [Full Text] [Related]
34. Nephrotic syndrome after cisplatin plus cyclophosphamide for ovarian carcinoma.
Beretta R; Cattaneo MT; Damiani E; Luchini S; Zucca E; Trabattoni A; Natale N
Cancer Treat Rep; 1986 Apr; 70(4):543-4. PubMed ID: 3698054
[No Abstract] [Full Text] [Related]
35. [Cytoreductive surgery plus combined chemotherapy for the treatment of advanced ovarian cancer].
Li M; Huang X
Zhonghua Fu Chan Ke Za Zhi; 1996 Oct; 31(10):621-3. PubMed ID: 9275460
[TBL] [Abstract][Full Text] [Related]
36. Re: Mucinous ovarian cancer.
Omura GA
Gynecol Oncol; 2005 Dec; 99(3):789; author reply 789-90. PubMed ID: 16125757
[No Abstract] [Full Text] [Related]
37. [A combination of cyclophosphamide, adriamycin and platinum (CAP) in the treatment of stage III and IV ovarian cancer].
Chylak V; Krusić J; Kolarić K
Jugosl Ginekol Perinatol; 1988; 28(1-2):41-3. PubMed ID: 3398564
[No Abstract] [Full Text] [Related]
38. Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease.
Ho CM; Huang YJ; Chen TC; Huang SH; Liu FS; Chang Chien CC; Yu MH; Mao TL; Wang TY; Hsieh CY
Gynecol Oncol; 2004 Jul; 94(1):197-203. PubMed ID: 15262142
[TBL] [Abstract][Full Text] [Related]
39. Quality of life in ovarian cancer patients: comparison of paclitaxel plus cisplatin, with cyclophosphamide plus cisplatin in a randomized study.
Bezjak A; Tu D; Bacon M; Osoba D; Zee B; Stuart G; Roy JA; Piccart M; Eisenhauer E
J Clin Oncol; 2004 Nov; 22(22):4595-603. PubMed ID: 15466785
[TBL] [Abstract][Full Text] [Related]
40. The impact of cisplat based chemotherapy on advanced ovarian cancer.
Prasad GR; Dalal AV; Tongaonkar HB; Chatterjee S; Kamat MR
J Postgrad Med; 1995; 41(4):95-8. PubMed ID: 10707728
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
